Clinical trials have shown that semaglutide and liraglutide are generally well tolerated, with gastrointestinal disorders being the most commonly reported AEs, including nausea, diarrhea, vomiting, and constipation, leading to dose reduction or temporary treatment interruption in 12.5% of study participants [40,41,42]
The 12mg dose is the highest tested in trials and produced the most weight loss (up to 28.7% of body weight)
We even include a link to a soothing Spotify playlist to play in the background if you wish
Prescription GLP-1 injections deliver FDA-approved pharmaceutical compounds that directly bind to GLP-1 receptors with pharmacologically validated effects on glucose and body weight
OASIS 4: oral semaglutide 25 mg produced mean weight loss of 13.6% at 64 weeks versus 2.2% for placebo (NEJM, 2025)
The GLP-1 six-in-one oral liquid is one example that has gained attention